Evaluation of PIMA Point-of-care CD4 Analyzer in Yunnan, China
Authors:
Open Access
- 5 April 2015
- journal article
- research article
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 128 (7) , 890-895
Abstract
Background: CD4 count is used to determine antiretroviral therapy (ART) eligibility. In China, flow cytometers are mostly located in urban areas with limited access by patients residing in remote areas. In an attempt to address this issue, we conducted a study to validate the performance of Alere PIMA point-of-care CD4 analyzer. Methods: Venous and finger-prick blood specimens were collected from HIV-positive participants from two voluntary counseling and testing sites in Yunnan Province. Both venous and finger-prick blood specimens were tested with the PIMA analyzer. Venous blood specimens tested with the Becton Dickinson FACSCalibur were used as a reference. Results: Venous specimens from 396 and finger-prick specimens from 387 persons were available for analysis. CD4 counts by PIMA correlated well with those from FACSCalibur with an R2 of 0.91 for venous blood and 0.81 for finger-prick blood. Compared to FACSCalibur, the PIMA analyzer yielded lower counts with a mean bias of − 47.0 cells/μl (limit of agreement, [LOA]: −204-110 cells/μl) for venous blood and −71.0 cells/μl (LOA: −295-153 cells/μl) for finger-prick blood. For a CD4 threshold of 350 cells/μl, the positive predictive value (PPV) of PIMA was 84.2% and 75.7% and the negative predictive value (NPV) was 97.6% and 95.8% for venous and finger-prick blood, respectively. For an ART threshold of 500 cells/μl, the corresponding PPV was 90.3% and 84.0% and NPV was 94.3% and 93.4%, respectively. Conclusions: CD4 counting using venous blood with PIMA analyzers is a feasible alternative to a large flow cytometer to determine ART eligibility.Keywords
This publication has 9 references indexed in Scilit:
- The Reliability of Point-of-Care CD4 Testing in Identifying HIV-Infected Pregnant Women Eligible for Antiretroviral TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2012
- Evaluation of PIMA point-of-care CD4 testing in a large UK HIV serviceSexually Transmitted Infections, 2012
- Evaluation of Portable Point-of-Care CD4 Counter with High Sensitivity for Detecting Patients Eligible for Antiretroviral TherapyPLOS ONE, 2012
- Performance evaluation of the Pima™ point‐of‐care CD4 analyser using capillary blood sampling in field tests in South AfricaJournal of the International AIDS Society, 2012
- Utility of the point of care CD4 analyzer, PIMA, to enumerate CD4 counts in the field settings in IndiaAIDS Research and Therapy, 2012
- Multisite Evaluation of a Point-of-Care Instrument for CD4+ T-Cell Enumeration Using Venous and Finger-Prick BloodJAIDS Journal of Acquired Immune Deficiency Syndromes, 2011
- Performance Evaluation of the Alere PIMA CD4 Test for Monitoring HIV-Infected Individuals in Resource-Constrained SettingsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2011
- Evaluation of the PIMA Point-of-Care CD4 Analyzer in VCT Clinics in ZimbabweJAIDS Journal of Acquired Immune Deficiency Syndromes, 2010
- STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENTThe Lancet, 1986